Why Medifast, Inc.’s (MED) Stock Is Up 13.83%
As of Tuesday, May 05, Medifast, Inc.’s MED share price has surged by 13.83%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions for weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements. It also provides lifestyle plans, which provides a targeted reset of the body’s metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all food groups or want a flexible meal plan to achieve a healthy weight; OPTAVIA Optimization Plan, a personalized approach to help clients’ long-term weight management; and OPTAVIA GLP-1 Nutrition Support Plan, a nutritional companion to GLP-1 medication that allows clients to focus on weight loss. In addition, the company offers metabolic synchronization, a science that reverses metabolic dysfunction through a targeted reset of the body’s metabolism. It markets its products through point-of-sale transactions executed over an e-commerce platform. The company serves health and wellness consumers. The company was formerly known as Healthrite, Inc. and changed its name to Medifast, Inc. in May 2001. Medifast, Inc. was incorporated in 1980 and is headquartered in Baltimore, Maryland.
Commentary & Analysis
Why Medifast, Inc.’s (MED) Stock Is Up 19.66%
As of Tuesday, May 05, Medifast, Inc.’s MED share price has surged by 19.66%, which has investors questioning if this is right time to sell.Tudor Pop
What You Need to Know About Medifast, Inc.'s Q2 Earnings
Medifast, Inc.'s fiscal Q2 earnings report was released on Monday, May 04. Let's dive in to see if (MED) missed or beat analyst's expectations.Tudor Pop
Why Medifast, Inc.’s (MED) Stock Is Down 5.23%
As of Thursday, February 19, Medifast, Inc.’s MED share price has dipped by 5.23%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Medifast, Inc.’s (MED) Stock Is Down 5.74%
As of Wednesday, February 18, Medifast, Inc.’s MED share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | MED | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $101.6 | $341.1 | 22% |
|
| Shares Out (Mil) | 11.0 | 22.7 | 22% |
|
| Institutional Ownership | 94.7% | 55.3% | 66% |
|
| Float (Mil) | 7.8 | 30.7 | 16% |
|
| Beta | 0.57 | 0.56 | 32% |
|
| Avg Daily Volume (000s) | 171 | 163 | 43% |
|
| Price Change (52-week) |
(30.8%) | 56.3% | 24% |
|
| Growth | MED | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (16.2%) | 2.3% | 3% |
|
| Net Income (5yr) | (16.9%) | (4.8%) | 23% |
|
| EPS (5yr) | (17.0%) | 2.3% | 16 |
|
| Dividends (5yr) | (14.9%) | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (13.2%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.650) | ($1.850) | ($0.600) | |
| Month Ago EPS | ($0.650) | ($1.850) | ($0.600) | |
| # Rev Up | 1 | 1 | na | |
| # Rev Down | 0 | 0 | na | |
| Three Months Ago EPS | ($0.430) | ($1.980) | ($2.760) | |
| Year/Year Chg | 236.8% | 8.8% | na | |
| Financials | MED | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $346 | $421 | 37% |
|
| Net Income (TTM) (Mil) | ($20) | $0 | 24% |
|
| EPS (TTM) | ($1.821) | $0.000 | 16% |
|
| Operating Cash Flow (TTM) (Mil) | $4 | $12 | 35% |
|
| Net Cash Flow (TTM) (Mil) | ($20) | $1 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $12 | $44 | 29% |
|
| Enterprise Value (Q1) (Mil) | ($23) | $334 | 1% |
|
| Valuation | MED | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.51 | 1.81 | 9% |
|
| P/E | na | 15.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.7 | na |
|
| Ratios | MED | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 70.1% | 64.3% | 81% |
|
| Net Margin | (5.8%) | 1.6% | 24% |
|
| ROA | (7.5%) | 1.3% | 27% |
|
| ROE | (9.8%) | 5.3% | 28% |
|
| Liabilities to Assets | 21.6% | 48.5% | 14% |
|
| F-Score | 3 | 4 | 19% |
|
Medifast, Inc. did not pass any screens on 7/30/2026.
